Cory Jubinville

Eddie Hickman

Lachlan Hanbury-Brown

Andrea Newkirk

Jason Gerberry

François Brisebois

Oren Livnat

Andreas Argyrides

Andrea Tan

Balaji Prasad

Matthew Caufield

Pavan Patel

- Tarsus Pharmaceuticals reported **$102.7 million** in net revenues for the last quarter and guided for **95,000 to 100,000 bottles distributed** for Q3.  **[1819790_tx_380328_0]**  Gross-to-net discounts are expected to improve to **43% to 45% for Q3** and reach the **low 40% by year-end**.  **[1819790_tx_380328_1]** 
- XDEMVY has achieved **over 90% insurance coverage** and has been prescribed by over **20,000 eye doctors**.  **[1819790_tx_380328_0]** **[1819790_tx_380328_2]**  The company is focusing on deepening prescribing patterns and increasing patient retreatment rates, which have recently exceeded **10%** towards a **20%** annualized target.  **[1819790_tx_380328_3]** **[1819790_tx_380328_4]** 
- The direct-to-consumer (DTC) campaign, with an expected spend of **$70 million to $80 million in 2025**, is driving demand and expanding the prescriber base.  **[1819790_tx_380328_3]** **[1819790_tx_380328_4]** 
- The pipeline includes **TP-04 for ocular rosacea**, with a Phase 2 trial starting later this year and data anticipated by the **end of next year or early the following year**.  **[1819790_tx_380328_7]** **[1819790_tx_380328_8]**  International expansion for XDEMVY is also underway, with potential European approval by **2027**.  **[1819790_tx_380328_6]**

Tarsus Pharmaceuticals Updates on XDEMVY Performance, Pipeline, and Market Strategy

Tarsus Pharmaceuticals (TARS)